Physician profile
Charles John Arnold
NPI 1508203266
$3,748.00
in general payments reported to CMS, 2019-2025
30 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $521 · 2021: $649 · 2022: $740 · 2023: $63.76 · 2024: $493 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,065.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $426.15 | 2019-2021 | |
| Smith+Nephew, INC. | $399.04 | 2019-2025 | Collagenase Santyl, Iodosorb Ointment 40g USA, Grafix |
| Organogenesis INC. | $353.26 | 2022-2025 | Apligraf, Affinity, Nushield |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.29 | 2019-2022 | |
| Abbvie INC. | $213.31 | 2021-2025 | |
| Melinta Therapeutics, LLC | $200.15 | 2019-2025 | Kimyrsa, Orbactiv |
| Dexcom, INC. | $176.19 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $155.63 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $150.59 | 2021 | |
| Amgen INC. | $142.50 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $129.07 | 2019 | |
| Glaxosmithkline, LLC. | $128.86 | 2019-2022 | |
| Kerecis Limited | $114.93 | 2022-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Novo Nordisk INC | $113.45 | 2020-2022 | |
| Astellas Pharma US INC | $113.20 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $111.40 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $91.58 | 2022 | |
| Polymedics Innovations INC. | $90.05 | 2024 | |
| Urgo Medical North America, LLC | $83.21 | 2024 | Urgoclean Ag, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Sunovion Pharmaceuticals INC. | $54.57 | 2019 | |
| Lilly USA, LLC | $50.35 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.00 | 2019 | |
| Reprise Biomedical, INC. | $22.64 | 2025 | Miro 3d |
| Paratek Pharmaceuticals, INC. | $21.92 | 2025 | Nuzyra |
| Lundbeck LLC | $17.71 | 2020 | |
| Derma Sciences, INC. | $17.29 | 2019 | |
| Tactile Systems Technology INC | $16.46 | 2025 | Flexitouch Plus, Nimbl |
| Reapplix INC. | $15.60 | 2025 | 3c Patch Kit - Box |
| Eisai INC. | $13.72 | 2021 | |
| Radius Health, INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.